Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 5, 2008

Agendia Offers Prognostic Tool for Breast Cancer

  • Agendia released TargetPrint®, a test that quantitatively determines the gene expression levels of the estrogen receptor, progesterone receptor, and HER2 in breast cancer tumor biopsies.

    TargetPrint runs on Agendia’s high-density chip, which received market clearance last month from the FDA

    “The test’s results give a precise molecular readout of prognostic parameters for breast cancer and provide physicians and patients with reliable guidance on the most suitable treatment for each individual patient,” says Richard A. Bender, M.D., CMO.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »